

REVIEW ARTICLE

Evolving hallmarks in urothelial bladder cancer: unveiling potential biomarkers



J. Afonso^{a,b,*}, R. Freitas^c, F. Lobo^c, A. Morais^c, T. Amaro^d, R. Reis^{a,b,e}, F. Baltazar^{a,b}, A. Longatto-Filho^{a,b,e,f}, L. Santos^{g,h} and J. Oliveira^c

^a Life and Health Sciences Research Institute - ICVS, University of Minho, Braga, Portugal

^b ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal

^c Department of Urology, Portuguese Institute of Oncology - IPO, Porto, Portugal

^d Experimental Pathology and Therapeutics Research Center, IPO, Porto, Portugal

^e Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

^f Laboratory of Medical Investigation (LIM 14), Faculty of Medicine, São Paulo State University, São Paulo, Brazil

^g Department of Surgical Oncology, IPO, Porto, Portugal

^h Faculty of Health Sciences, University Fernando Pessoa - UFP, Porto, Portugal

Received 10 May 2014; accepted 5 January 2015

KEYWORDS

Urothelial bladder carcinoma;
Biomarkers;
Neovascularization;
Metastasis suppressors;
Tumour metabolism

Abstract

Urothelial bladder carcinoma (UBC), the most frequent type (90%) of bladder cancer and the second most common malignancy of the urogenital region, is a relatively well understood type of cancer, with numerous studies concerning pathogenetic pathways, natural history and bladder tumor biology being reported. Despite this, it continues to remain a challenge in the oncology field, mostly due to its relapsing and progressive nature, and to the heterogeneity in the response to cisplatin-containing regimens. Although the formulae based on clinical staging and histopathological parameters are classically used as diagnostic and prognostic tools, they have proven insufficient to characterize the individual biological features and clinical behaviour of the tumours. Understanding the pathobiology of the disease can add important information to these classical criteria, and contribute to accurately predict outcome and individualize therapy for UBC patients. In this line of investigation, we found that tumour angiogenesis and lymphangiogenesis, the process of invasion and metastasis and the energy metabolism reprogramming / tumour microenvironment encompass several potential biomarkers that seem to influence bladder cancer aggressiveness and chemoresistance. We particularly highlight the roles of lymphovascular invasion, and of RKIP, CD147 and MCT1 immunoexpressions, as relevant prognostic and/or predictive biomarkers, and as promising areas of therapeutic intervention, eliciting for the development of additional studies that can validate and further explore these biomarkers. © 2015 Associação Portuguesa de Urologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

* Autor de correspondência.

Email: juliettaafonso@eceaude.uminho.pt (J. Afonso).

PALAVRAS-CHAVE

Carcinoma urotelial da bexiga;
Biomarcadores;
Neovascularização;
Moléculas supressoras de metástases;
Metabolismo tumoral

Características biológicas do carcinoma urotelial da bexiga: à descoberta de potenciais biomarcadores**Resumo**

O carcinoma urotelial da bexiga (CUB), o tipo de cancro mais frequente deste órgão (90%) e o segundo mais comum da região genitourinária, está relativamente bem caracterizado, fundamentado por inúmeros estudos sobre vias patogénicas, histogénese e biologia tumoral. No entanto, permanece como um desafio na oncologia, principalmente devido à sua elevada taxa de recidiva e progressão, e à heterogeneidade na resposta a tratamentos de quimioterapia contendo cisplatina. As fórmulas baseadas no estadiamento tumoral e em parâmetros histopatológicos, embora geralmente utilizadas como ferramentas de diagnóstico e prognóstico, são insuficientes para caracterizar as propriedades biológicas e o comportamento clínico dos tumores. A compreensão detalhada da patobiologia da doença poderá adicionar informações importantes aos critérios clássicos, e contribuir para uma correta previsão individual do prognóstico e da terapêutica a utilizar nos doentes com CUB. Nesta linha de investigação, o nosso grupo sugere que na angiogénese e na linfangiogénese tumoral, no processo de invasão e metastização e na reprogramação do metabolismo energético / microambiente tumoral estão implicados potenciais biomarcadores que parecem influenciar a agressividade tumoral e a resistência à quimioterapia no CUB. Salienta-se o papel da invasão linfovascular, e da imunoexpressão das moléculas RKIP, CD147 e MCT1, como biomarcadores de prognóstico e/ou preditivos de resposta à terapêutica, e como áreas promissoras de intervenção terapêutica. É urgente desenvolver estudos adicionais que continuem a explorar e, eventualmente, validar as potencialidades destes biomarcadores.

© 2015 Associação Portuguesa de Urologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob a licença de CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Thirteen years ago, Hanahan and Weinberg suggested that, although encompassing variable mechanistic strategies, cancers in general acquire a set of functional biological capabilities during their multistep development. These include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.¹ In their recent review, the authors added to their previous model two enabling characteristics and two emerging hallmarks. They considered that genome instability generates the genetic diversity underlying the acquisition of all hallmarks, and that inflammation promotes multiple hallmark functions. Additionally, the establishment of a tumour microenvironment by the malignant cells but also by recruited normal cells importantly contributes to energy metabolism reprogramming and immune destruction evasion in order to effectively support neoplastic proliferation.² This molecular knowledge is already being applied into clinical practice, with targeted therapies that interfere with each of the hallmarks being developed and entering in clinical trial phase or, in some cases, being approved for clinical use in treating certain forms of human cancer.³⁻⁵

In urothelial bladder cancer (UBC) setting, although a reasonable number of biomarkers seem to be prognostically relevant,^{6,7} there is a substantial delay in the translation into the clinics, and clinical trials with molecularly targeted agents have been few in number and largely unsuccessful.^{8,9}

This is probably due to the unique complexity involved in the dual-track pathway of bladder carcinogenesis, which postulates that UBC develops via two distinct but somewhat overlapping pathways, resulting in two main phenotypic variants with different biological behaviours and prognoses.¹⁰ However, areas in which biomarkers may prove valuable are evident, encompassing the three most important risk factors that threaten survival and life quality of bladder cancer patients.⁷ First, the majority of UBCs emerge as non-muscle invasive (NMI), low grade, papillary lesions. Due to their high risk of recurrence, current guidelines recommend intense follow-up that classically relies on invasive techniques such as cystoscopy and biopsy, causing significant patient discomfort and implicating substantial costs. Thus, prediction of tumour recurrence through non-invasive methods would be of great value.¹¹ Second, an important proportion of NMI tumours, such as high grade or carcinoma *in situ* lesions, incur at an increased risk of progression to muscle-invasive (MI) disease. Timely prediction of progression would guide a vigilant surveillance, and would help clinicians to identify patients in need of early, aggressive management, while avoiding over-treatment in others.¹² Third, the risk of metastasis is the main pitfall for MI-UBC patients, and the majority of bladder cancer deaths occur as a consequence of metastatic disease.¹³ Although cisplatin-containing chemotherapy is recommended for locally-advanced or metastatic UBC,¹⁴ survival benefits are impaired in up to 50% of the patients due to chemoresistance and patient fragility.¹⁵ In this scenario, robust biomarkers could help to identify circulating or lymph-node occult micrometastases,

could represent potential therapeutic targets, and could forecast and stratify responses to conventional cytotoxic therapies or to emerging targeted therapies (the so called companion biomarkers).^{9,16-18} Hence, UBC represents a considerable opportunity and challenge for biomarkers' research.

In the last years, efforts have been taken to uncover prognostic and/or predictive biomarkers that might be useful in the clinical care of UBC patients. Traditional approaches of single-molecule or single-pathway profiling are being replaced by investigations on panels of biomarkers encompassing several hallmarks of cancer.^{7,19,20} While the few biomarkers of potential clinical relevance that have been identified so far are mainly related to the key molecular pathways of bladder tumourigenesis [e.g. FGFR3 (fibroblast growth factor receptor 3) and TP53 (tumour protein p53) mutations],^{6,7,21} there is the need to expand the research into poorly explored scenarios of the malignant phenotype, in an attempt to unveil novel promising markers that can be integrated into a molecular signature with accurate prognosis and predictive power. A cancer-related biomarker must be a molecule produced by the tumour, detectable and measurable in patient specimens (tissue, blood or urine), representative of various tumour properties, and reproducible, specific and sensitive.^{7,22} Several recent reviews have explored the most promising UBC biomarkers, although, to date, no biomarker panel has reached validation for daily clinical practice.^{6,7,21,23} Immunohistochemical approaches in tissue arrays are well suited for the detection task, by being practical methods that can easily allow the translation of new described biomarkers into clinical practice.²⁴ In this line of investigation, our group used immunohistochemistry to study, in a cohort of well-characterized UBC samples, the clinical and prognostic significance of several poorly studied putative biomarkers encompassing and overlapping three hallmarks of cancer: inducing tumour angiogenesis (and lymphangiogenesis), activating invasion and metastasis, and reprogramming cellular energetics and the tumour microenvironment. We additionally performed validation assays with bladder cancer cell lines. Our research efforts have resulted in important findings concerning some biological parameters that seem to influence bladder cancer aggressiveness and chemoresistance. In the next sections, we will explore the state of the art of these evolving hallmarks, and provide our contribution in unveiling potential prognosis and predictive biomarkers, as well as new therapeutic targets, also reviewing the contribution of other authors to the current knowledge on this field.

Tumour angiogenesis and lymphangiogenesis

The dissemination of malignant cells to distant organs from the primary tumour is the leading cause of mortality from cancer and, with few exceptions, all cancers can metastasize.^{25,26} Although metastasis can occur by local tissue invasion and direct seeding of body cavities, the main routes of dissemination are the hematogenous and lymphogenous spread. Preclinical and clinical studies suggest that the lymphatic vascular system is preferred over the blood vascular

system, and occurrence of lymph node metastasis is an important factor for patients' prognosis and treatment decision-making.^{27,28} The malignant cells exploit both vascular systems by expressing growth factors that alter the normal pattern of blood and lymphatic vessel growth, creating conduits for metastasis to occur by tumour-induced angiogenesis and lymphangiogenesis.²⁹

The overexpression of angiogenic and lymphangiogenic growth factors in tumours significantly increases blood vessel density (BVD) and lymphatic vessel density (LVD), and establishes the routes for blood vessel invasion (BVI) and lymphatic vessel invasion (LVI) by malignant cells. A significant number of retrospective studies reported significant associations between the occurrence of angiogenesis and BVI, lymphangiogenesis and LVI, and the risk of tumour recurrence, progression, lymph node metastasis, distant metastasis and death for distinct cancer patients.^{29,30} Blocking the expression of angiogenic and lymphangiogenic growth factors in preclinical models has inhibited tumour growth and expansion of the tumour-associated vasculature, and reduced malignant spread.^{31,32} Therefore, it is not surprising that novel anti-angiogenic/lymphangiogenic agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are currently under clinical trial phase or have already obtained the approval from the Food and Drug Administration for treating cancer patients.

Similarly to other types of cancer, the role of angiogenesis in UBC is well established. Both VEGF (vascular endothelial growth factor) levels and high BVD counts independently predicted progression and lymph node metastasis, significantly lowering survival rates.³³⁻³⁵ Large scale approaches have also confirmed VEGF as an independent prognosis factor.³⁶ Moreover, although studies on lymphangiogenesis occurrence and its usefulness in urothelial malignancies are fewer in number, the general tendency points out for an important task of lymphatic vessel formation in malignant dissemination.^{37,38} VEGF-C levels were associated with high lymphatic vessel density (LVD) counts, predicting lymph node metastasis.^{38,39} Both blood and lymphatic vessels participate in the metastatic cascade, and lymphovascular invasion (LI) has been identified as an independent prognostic factor for recurrence and overall survival.⁴⁰ Importantly, it has been demonstrated that the LI status helps to stratify NO UBC patients who are at increased risk of bladder cancer recurrence and death.⁴¹ Despite these important associations, LI occurrence is not routinely described on the pathology reports, due to the lack of diagnosis reproducibility.^{42,43}

In our research, we assessed angiogenesis, lymphangiogenesis and lymphovascular invasion occurrence in 83 UBC tissue sections, using an immunohistochemical method to differentiate between blood and lymphatic endothelial cells⁴⁴ (Table 1). We did observe that tumour neovascularization occurrence (Figs. 1A and 1B) determines bladder cancer aggressiveness, although no significant association with outcome variables was found. While contradicting a few prior reports,^{34,35} others have also failed to demonstrate correlations among BVD and prognosis,⁴⁵ and it has been advocated that, due to the inconsistency among various studies, BVD alone does not capture the real effect of angiogenesis occurrence on tumour progression and metastasis.

Table 1 Selected studies on urothelial bladder cancer biomarkers.

Markers	Cohort	n	Major findings	Ref
BVD	RC	83	LVD associated with tumour aggressiveness. Identification of LI was significantly improved when using vessel markers. BVI and LVI significantly lowered DFS and OS. BVI remained as an independent prognostic factor for OS	44
LVD BVI LVI				
p-mTOR	RC	76	p-mTOR expression decreased with increasing stage, and was lost from non-tumour to tumour urothelium. pT3/pT4 positive cases had a significant worse DFS rate	61
RKIP	RC	81	RKIP expression associated with a favourable clinicopathological profile. Loss of RKIP expression associated with LVI occurrence, and significantly lowered DFS and OS, remaining as an independent prognostic factor for DFS	66
MCT1 MCT4 CD147	RC and TUR	114	MCT1, MCT4 and CD147 expressions significantly associated with unfavorable clinicopathological parameters and poor prognosis. In selected platinum treated-patients, OS was significantly lower for those with MCT1+CD147 positive tumours	71
Scoring model*	RC	77	The model was stronger in predicting prognosis than the individual parameters, remaining as an independent prognostic factor for DFS and OS. CD147 expression added significant prognostic information to the model	51

BVD: blood vessel density; BVI: blood vessel invasion; DFS: disease-free survival; LVD: lymphatic vessel density; LVI: lymphatic vessel invasion; LI: lymphovascular invasion; MCT: monocarboxylate transporter; OS: overall survival; p-mTOR: phospho-mammalian target of rapamycin; RC: radical cystectomy; RKIP: Raf kinase inhibitor protein; TUR: transurethral resection.

* Scoring model: includes clinicopathological parameters - stage and grade - combined with three biological parameters - BVI, LVI and CD147 overexpression.

sis.²¹ On the other hand, in our study it was noted that intratumoural lymphatic vessels, described as collapsed and non-functional by some authors,^{46,47} had visible lumens in a significant proportion of cases, and no edema was observed, which supports an efficient lymphatic flow (Fig. 1B). Moreover, these intratumoural vessels, when functional, seem to actively cooperate in malignant dissemination, as observed by the presence of single malignant cells in the well-preserved intratumoural lymphatic vessels (Fig. 1D), which portended a low overall survival rate. Similar results have been obtained by others.⁴⁸ Additionally, the specific staining of blood and lymphatic endothelium significantly contributed to an accurate evaluation of LI occurrence, and to a specific distinction between BVI and LVI (Figs. 1C and 1D). This was particularly important in the accurate detection of isolated malignant cells invading lymphatic capillaries, which have a higher propensity to survive in the lymphatic flow, when comparing with the rigors of the blood circulation. In fact, malignant emboli - easily detectable in hematoxylin and eosin (H&E) stained sections if no stromal retraction is observed - are more prone to invade the chaotic and hyperpermeable structure of the blood vasculature and to overcome the hostilities inherent to blood flow, such as serum toxicity, high shear stress and mechanical deformation.⁴⁹ Conversely, lymph flows slowly, and has a composition similar to interstitial fluid, being ideal for the survival and dissemination of single malignant cells.⁵⁰ These are more difficult to detect in H&E sections. Thus, the specific staining of lymphatic endothelium contributes to accurately diagnose LVI occurrence (Fig. 1D), which significantly im-

pairs overall survival, as well as BVI by malignant emboli (Fig. 1C). BVI was identified as an independent prognostic factor in our cohort. In another study where we developed a model of bladder cancer aggressiveness by the combined analysis of clinicopathological - stage and grade - and biological - specifically highlighted BVI and LVI, and CD147 expression - parameters⁵¹ (Table 1), we found that BVI and LVI clearly contributed to separate between low and high aggressiveness groups. BVI and LVI occurrence may, therefore, represent potential prognostic biomarkers that can guide personalized selection of patients likely to benefit from perioperative chemotherapy regimens and/or targeted therapies. In accordance, a recent review has emphasized that LI should be routinely reported in the pathological report, and that immunohistochemistry identification of blood and lymphatic vessels should be employed in histologically equivocal cases for confirmation.⁴³

Angiogenesis and lymphangiogenesis represent potential targets for therapeutic intervention in the UBC setting, and several compounds targeting the most relevant neovascularization signalling pathways are being tested in clinical trials.⁵² However, caution is recommended, due to the risk of refractoriness to VEGFs/VEGFRs signalling blockade.⁵³ In fact, compensation mechanisms to VEGF abrogation in UBC cells lines have been described.⁵⁴ In alternative, the mammalian target of rapamycin (mTOR) intracellular pathway, besides transducing signals that activate the translational machinery and promote cell growth,⁵⁵ is also an important signalling mediator in hypoxia-induced angiogenesis.⁵⁶ Some rapamycin analogues have demonstrated anti-angiogenic




Figure 1 CD31 and D2-40 immunoections in urothelial bladder carcinoma. Intratumoral blood vessels highlighted by CD31 (A, $\times 100$ amplification, and C, $\times 400$ amplification), and intratumoral lymphatic vessels highlighted by D2-40 (B and D, $\times 400$ amplification), in invasive urothelial carcinoma. Evidence of internal negative control in B (* D2-40 negative blood vessel). A small malignant embolus and an isolated malignant cell are invading intratumoral blood (C) and lymphatic (D) vessels (adapted from Afonso et al.⁴⁴).

effects in UBC pre-clinical⁵⁷ and clinical trials.⁵⁸ Nevertheless, the levels of mTOR activation in UBC tissue sections have been poorly explored, and controversial results were found.^{59,60} We assessed phospho-mTOR (p-mTOR) levels in a series of 76 UBC sections with representative tumour and non-tumour (normal-like or hyperplastic) areas, where blood and lymphatic vessels were also stained by immunohistochemistry, in order to correlate angiogenesis and lymphangiogenesis occurrence with p-mTOR expression⁶¹ (Table 1). No significant associations were found between the clinicopathological parameters and vascular density, and p-mTOR expression. Even though, we observed that p-mTOR decreased with increasing stage, and was lost from non-tumour to tumour urothelium, particularly in MI lesions, where immunoection was observed in a few spots of cells. Angiogenesis occurrence was impaired in pT3/pT4 negative tumours; conversely, pT3/pT4 positive cases had worse survival rates, as reported by other authors.⁵⁹ In NMI tumours, p-mTOR was evenly distributed within the malignant urothelium, although staining was stronger at the superficial layers of cells (Fig. 2A), resembling the pattern of expression that was observed in the non-tumour urothelium, where p-mTOR expression was restricted to umbrella cells and some superficial cells of the intermediate layer (Fig. 2B). This pattern of expression has been similarly described in other studies.⁵⁹ We hypothesized that umbrella cells from non-tumour urothelium express p-mTOR constitutively, as part of their metabolic plasticity, and that NMI lesions with increasing malignant potential extend immunoection to the inner layers. The two patterns among MI tumours - absence of expression or expression in cell clusters - probably indicate divergent biological scenarios encompassing the mTOR pathway. Additional studies with




Figure 2 p-mTOR immunoection in normal and malignant urothelium. A, non-muscle invasive papillary tumour expressing cytoplasmic p-mTOR in a heterogeneous pattern ($\times 100$ amplification), with the luminal and intermediate cell layers being more intensely stained than the layer of basal cells. B, normal urothelium ($\times 400$ amplification) exhibiting cytoplasmic p-mTOR immunoection restricted to the superficial layers (adapted from Afonso et al.⁶¹).

larger and more comprehensive UBC series and panels of mTOR upstream and downstream effectors, together with reproducible immunohistochemical and molecular approaches, and with *in vivo* and *in vitro* bladder tumour models, are urgently needed to clarify the backstage of the mTOR pathway in human urothelial bladder cancer, in order to expedite the research on potential target therapeutic approaches.

Invasion and metastasis

Tumour metastasis, the most fearsome aspect of cancer, is a multistage process during which malignant cells separate from the primary tumour and invade discontinuous organs. Angiogenesis and lymphangiogenesis, as already mentioned, are essential for invasion and metastasis to occur, but numerous additional events are also necessary for the success of the metastatic spread. In fact, a long series of sequential, rate limiting, interrelated steps must occur, involving the physical translocation of a malignant cell to a distant organ, and the ability of that cell to develop into a metastatic lesion at the distant site. The final result depends not only on the intrinsic properties of the tumour cells, but also on the host responses.⁶²

High risk NMI and, more often, MI-UBC, carry a significant threat of invasion and metastasis despite radical surgical treatment.¹³ Timely detection of biomarkers that enable malignant cells with invasive and metastatic properties would allow identifying patients that could benefit from early aggressive approaches such as radical cystectomy and perioperative chemotherapy, and would guide the development of targeted therapies. Conversely, while inhibiting

biomarkers of invasion and metastasis emerges as an attractive therapeutic strategy, restoring the function of metastasis suppressor proteins is not less appealing. In this scenario, the role of the metastasis suppressor RKIP (Raf kinase inhibitor protein) in cancer has been highlighted due to its ability to modulate several intracellular signalling cascades involved in cell differentiation, cell cycle kinetics, apoptosis, epithelial to mesenchymal transition and cell migration.⁶³ Given its pleiotropic abilities in maintaining cellular equilibrium, it is not surprising that RKIP down-regulation associates with metastatic events in an increasing number of solid tumours.⁶⁴ Its preponderance in UBC setting is largely unknown, although low mRNA levels have been reported in NMI tumours, when compared with normal urothelium.⁶⁵

We evaluated RKIP expression in a cohort of 81 tumour sections from UBC patients. Blood and lymphatic vessels were also assessed, in order to correlate BVI and LVI occurrence with RKIP levels⁶⁶ (Table 1). To the best of our knowledge, this was the first study evaluating RKIP immunorexpression in bladder cancer tissue samples. We observed a homogeneous expression of RKIP in normal urothelium (Fig. 3A) and in tumour sections with a favourable clinicopathological profile, namely NMI tumours where LVI was absent (Fig. 3B). Conversely, a heterogeneous pattern of expression, with loss of RKIP expression intensity from the tumour centre to the invasion front, was associated with LVI occurrence (Fig. 3C). Moreover, low RKIP expression significantly lowered disease-free and overall survival, remaining as an independent prognostic factor for disease-free survival. RKIP loss or diminution had been previously reported in other types of aggressive cancers, significantly impairing prognosis. Clinically, RKIP expression is higher in benign tumors than in malignant tissues while its expression is completely absent in metastases.⁶³ Additional studies in bladder cancer setting need to be urgently developed, in order to confirm our promising results and to expand the research into therapeutic strategies that can potentially restore RKIP functionality. Besides acting as a prognostic biomarker, RKIP status may also have a role as a predictive biomarker, once it has been demonstrated that its expression may potentiate apoptosis induced by chemotherapeutic agents, which might be useful in defining therapy response profiles.^{67,68}

Energy metabolism reprogramming and the tumour microenvironment

Altered energy metabolism, although only recently emerged as a new hallmark of cancer,² is proving to be as widespread in tumour cells as the classical traits of malignancy. In fact, cancer growth is characterized by deregulated cell proliferation and corresponding adjustments of energy metabolism, such as the adoption of the Warburg effect. This necessarily involves different inputs to the tumour microenvironment, namely the extrusion of high amounts of lactate from the malignant cells that will sculpt an acid-resistant phenotype, which supports increased migration and invasion, favouring metastasis.^{69,70} Molecules and pathways involved in this intricate backstage of malignancy potentially represent new areas of therapeutic intervention.




Figure 3 RKIP immunorexpression in normal and malignant urothelium. A, immunohistochemical positive reaction for RKIP in normal urothelium ($\times 200$ amplification). B, a non-invasive papillary tumour showing a homogeneous pattern of expression ($\times 100$ amplification). C, an infiltrating tumour exhibiting a heterogeneous pattern, with the tumour core being more intensely stained than the invasive front ($\times 100$ amplification) (adapted from Afonso et al.⁶⁶).

The biological mechanisms that reprogram cellular energetics and model the tumour microenvironment are poorly characterized in bladder cancer. Thus, we elected a panel of three microenvironment-related molecules and investigated their expressions in a subset of tumour tissue sections from 114 UBC patients treated by transurethral resection and/or radical cystectomy⁷¹ (Table 1). The central player was CD147, a tumor cell surface molecule implicated in extracellular matrix remodeling, angiogenesis and tumour growth, and related with chemoresistance-promoting events.⁷² We had previously demonstrated the prognostic impact of CD147 overexpression in bladder cancer patients, when we developed a model of UBC aggressiveness that included clinicopathological and biological parameters⁵¹ (Table 1). In fact, CD147 expression was largely preponderant in the high aggressiveness group, and clearly added prognostic information to the model. For that reason, we decided to re-evaluate this glycoprotein in a larger series, together with other molecular companions. Thus, we observed that CD147 was upregulated in bladder tumour tissue (Fig. 4A), significantly associating with a dismal clinicopathological profile and poor prognosis. Other authors have identified CD147 expression in UBC as an independent prognostic biomarker,^{73,74} and have additionally




Figure 4 CD147, MCT1 and MCT4 immunoexpressions in urothelial bladder carcinoma. Muscle-invasive tumours exhibiting cytoplasmic and membrane immunoreactivity of CD147 (A, $\times 200$ amplification), MCT1 (B, $\times 200$ amplification) and MCT4 (C, $\times 100$ amplification) in the malignant urothelium, with negative stromas (adapted from Afonso et al.⁷¹).

proposed it as a predictive biomarker in the setting of cisplatin-containing regimens.⁷⁴ To confirm this hypothesis, we established four CD147-expressing UBC cell lines and studied the effect of cisplatin treatment on cell viability, cell cycle distribution and cell death, as well as on the migration and invasion abilities of the cells. CD147 expression was then downregulated in a cisplatin less-sensitive cell line (Fig. 5A). Importantly, we found that CD147 downregulation clearly increased chemosensitivity to cisplatin (Fig. 5B). To the best of our knowledge, this was the first *in vitro* study demonstrating that CD147 depletion in UBC cells enhances the therapeutic action of cisplatin, highlighting this molecule as a potential prognostic and predictive biomarker.

In order to further elucidate CD147 interactions, we also analyzed monocarboxylate transporter (MCT) expressions in the cohort of 114 UBC patients⁷¹ (Table 1). MCTs, particularly MCT1 and MCT4, play a key role in the promotion of the hyper-glycolytic acid-resistant phenotype, by exporting lactate from the glycolytic malignant cells to the tumour microenvironment.⁷⁵ CD147 has been described as a chaperone for the proper expression of MCTs at the plasma membrane,⁷⁶ and our results support that function. In fact, we found significant associations among MCT1, MCT4 and CD147 expressions. MCT1 and MCT4 were upregulated in




Figure 5 Effect of CD147 downregulation in HT1375 cell line on the expression of MCTs and on chemosensitivity to cisplatin (treatment with cisplatin between days 5 and 8 after reverse transfection). A, CD147, MCT1 and MCT4 immunoexpressions in HT1376 control cells, and Western blot analysis of CD147, MCT1 and MCT4 expressions in control/scramble HT1376 cells and in siCD147 HT1376 cells, showing that CD147 silencing was accompanied by a decrease in MCT1 and MCT4 expressions. B, effect of cisplatin on the viability of scramble and siCD147-HT1376 cells, as detected by the MTS assay after 72 hours of treatment, showing that siCD147 cells were more sensitive to cisplatin (adapted from Afonso et al.⁷¹).

highly aggressive tumours (Fig. 4B and 4C), and MCT1 overexpression impaired overall survival. In accordance, a recent study demonstrated the independent prognostic significance of MCT1 and MCT4 in UBC⁷⁷; their upregulation has also been observed in other malignancies.⁷⁸ Interestingly, a CD147 and MCT1 double-positive profile was significantly associated with unfavourable clinicopathological parameters and poor prognosis in our UBC series, and discriminated a poor prognosis group in cisplatin-treated patients. We hypothesized that MCT1 cooperates with CD147 in the promotion of a chemoresistance phenotype and, possibly, of other

functions that are primarily attributed to CD147. In fact, it appears that CD147 maturation is affected by MCT expression.⁷⁹ In our *in vitro* study, CD147 depletion was accompanied by a marked decrease in the expression of MCT1 and MCT4 (Fig. 5A), which suggests CD147 as an MCT1/4 chaperone. It would be interesting to silence MCT1 expression in the UBC cell line and to study CD147 expression levels, in order to confirm the opposite.

Overall, our results point out for an important role of CD147 and their companions in promoting a highly aggressive phenotype where glycolysis is upregulated, contributing to acidify the tumour microenvironment, enabling the malignant cells with growth, migration, invasion and chemoresistance abilities that can only be overcome if new approaches of target therapeutic intervention are investigated.

The utility of combining distinct biomarkers - practical implications

Currently, there is no doubt that inclusion of prognostic and predictive biomarkers into the classical instruments of diagnosing the disease and predicting outcomes, such as risk stratification tables,^{80,81} nomograms^{82,83} and artificial neural networks,^{84,85} would certainly refine diagnosis, prognosis and therapeutic decision, with several studies demonstrating the potential impact of developing risk stratification tools that integrate clinicopathological and biological parameters.^{51,86,87} Moreover, it seems that combining biomarkers inherent to different cancer hallmarks improves predictive accuracy over one biomarker abnormality, as several biomarkers may help to elucidate individual biological features of the tumours.^{12,20,51,88-90} As it was previously mentioned, we developed a model of tumour aggressiveness by the combined analysis of two clinicopathological parameters - stage and grade - with three biological parameters - BVI, LVI and CD147 overexpression⁵¹ (Table 1). Therefore, we included biomarkers that are mainly associated with angiogenesis (BVI), lymphangiogenesis (LVI), energy metabolism reprogramming, invasion and chemoresistance (CD147). The parameters included in the model had individual prognostic impact on the 77 UBC patients that were studied, as demonstrated in univariate analysis. However, the model was stronger in predicting prognosis, clearly separating a low aggressiveness from a high aggressiveness group, and remaining as an independent prognostic factor for disease-free (Fig. 6A) and overall survival (Fig. 6B). If an additional biomarker was included in the model, namely immunoexpression of the metastasis suppressor RKIP, its accuracy would be further enhanced (data not shown). Therefore, combining distinct biomarkers with the classical clinicopathological parameters will have undeniable impact for UBC patients, who may benefit, in the future, from accurate prediction of outcomes and response to therapy, and guided targeted therapy.

Conclusion

Bladder cancer, being the second most common malignancy of the urogenital region, represents a significant epidemio-




Figure 6 Survival analysis of urothelial bladder cancer patients based on a tumour aggressiveness scoring system. 5-year disease-free survival (A) and 5-year overall survival (B) based on a tumour aggressiveness scoring system that includes T3/T4 pathologic stage, grade III, occurrence of blood vessel invasion by malignant emboli, occurrence of lymphatic vessel invasion by isolated malignant cells and CD147 overexpression (n=77) (adapted from Afonso et al.⁵¹).

logical problem, mostly due to its heterogeneous natural history and clinical behavior. Validated biomarkers would certainly help to elucidate unique biological features that may allow identifying patients who are at increased risk of recurrence, progression, metastasis and/or chemorefracto-

ry relapse. In addition, biomarkers may improve prediction of response to therapy and guide us to a new era of tailored and targeted treatment. Current research efforts are directed into the elaboration of nomograms that can combine well-established clinicopathological parameters with novel putative biomarkers. In this line of investigation, we suggest that lymphovascular invasion occurrence, and RKIP, CD147 and MCT1 expressions might be relevant prognostic and/or predictive biomarkers, and promising areas of therapeutic intervention, eliciting for the development of additional studies that can validate and further explore the potentialities of our work. We additionally stand up for the specific staining of blood and lymphatic endothelium by immunohistochemistry in histologically equivocal cases that require confirmation, in order to identify images of lymphovascular invasion that could be missed during the classical evaluation on H&E stained tumour sections, and to allow an accurate discrimination between the two forms of lymphovascular invasion. There is the urgent need to transpose these and other biomarker tests on small groups of patients to large-scale independent validation assays, encompassing multi-institutional collaborations, so that prospective validations and randomized trials based on the retrospective findings may then proceed.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100:57-70.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646-74.
- Wu J, Joseph SO, Muggia FM. Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact. *Oncology (Williston Park)*. 2012;26:936-43.
- Joseph SO, Wu J, Muggia FM. Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration. *Oncology (Williston Park)*. 2012;26:1021-30, 35.
- Jungic S, Tubic B, Skrepnik T. The role of biomarkers in the development of novel cancer therapies. *Drug Metabol Drug Interact*. 2012;27:89-99.
- Xylinas E, Kluth LA, Lotan Y et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urol Oncol*. 2014;32:230-42.
- Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. *Hum Pathol*. 2011;42:455-81.
- Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. *Cancer Metastasis Rev*. 2009;28:355-67.
- Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? *Nat Rev Urol*. 2012;9:41-51.
- Spiess PE, Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. *Arch Pathol Lab Med*. 2006;130:844-52.
- Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. *Eur Urol*. 2010;57:12-20.
- van Rhijn BW. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. *Urol Oncol*. 2012;30:518-23.
- Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. *Lancet*. 2009;374:239-49.
- Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2011;22 Suppl 6:vi45-9.
- Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*. 2006;176(6 Pt 1):2414-22; discussion 2422.
- Bellmunt J, Albiol S, Suarez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. *Crit Rev Oncol Hematol*. 2009;69:211-22.
- Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. *Clin Chem*. 2013;59:1447-56.
- Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. *Curr Opin Urol*. 2011;21:420-7.
- Bartsch G, Mitra AP, Cote RJ. Expression profiling for bladder cancer: strategies to uncover prognostic factors. *Expert Rev Anticancer Ther*. 2010;10:1945-54.
- Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer*. 2008;112:315-25.
- Rink M, Cha EK, Green D, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Curr Urol Rep*. 2012;13:122-35.
- Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. *EPMA J*. 2013;4:7.
- Wadhwa N, Jatawa SK, Tiwari A. Non-invasive urine based tests for the detection of bladder cancer. *J Clin Pathol*. 2012;65:970-5.
- Matsushita K, Cha EK, Matsumoto K, et al. Immunohistochemical biomarkers for bladder cancer prognosis. *Int J Urol*. 2011;18:616-29.
- Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. *Int J Biochem Cell Biol*. 2009;41:1452-62.
- Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Res*. 2010;70:5649-69.
- Achen MG, Stacker SA. Molecular control of lymphatic metastasis. *Ann N Y Acad Sci*. 2008;1131:225-34.
- Christiansen A, Detmar M. Lymphangiogenesis and cancer. *Genes Cancer*. 2011;2:1146-58.

29. Holopainen T, Bry M, Alitalo K, Saari A. Perspectives on lymphangiogenesis and angiogenesis in cancer. *J Surg Oncol*. 2011;103:484-8.
30. Afonso J, Santos LL, Longatto-Filho A. Angiogenesis, lymphangiogenesis and lymphovascular invasion: prognostic impact for bladder cancer patients. In: Canda A, editor. *Bladder cancer - from basic science to robotic surgery*. Croatia: INTECH Open Access Publisher; 2012.
31. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. *Cancer Gene Ther*. 2008;15:776-86.
32. Zhang D, Li B, Shi J, et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. *Cancer Res*. 2010;70:2495-503.
33. Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. *Ann Oncol*. 2003;14:1419-24.
34. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. *Int Urol Nephrol*. 2004;36:401-5.
35. Chaudhary R, Bromley M, Clarke NW, et al. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. *Anticancer Res*. 1999;19:3479-84.
36. Pignot G, Bieche I, Vacher S, et al. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. *Eur Urol*. 2009;56:678-88.
37. Fernandez MI, Bolenz C, Trojan L, et al. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. *Eur Urol*. 2008;53:571-8.
38. Zhou M, He L, Zu X, Zhang H, Zeng H, Qi L. Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder. *BJU Int*. 2011;107:1930-5.
39. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. *BJU Int*. 2006;98:1090-3.
40. Shariat SF, Svatek RS, Tilki D, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int*. 2010;105:1402-12.
41. Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. *BJU Int*. 2010;106:493-9.
42. Algaba F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. *Curr Opin Urol*. 2006;16:367-71.
43. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Clinicopathological significance of lymphovascular invasion in urothelial carcinoma. *Anal Quant Cytol Histol*. 2012;34:173-9.
44. Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion-the prognostic contribution of related molecular markers. *Histopathology*. 2009;55:514-24.
45. Shariat SF, Youssef RF, Gupta A, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. *J Urol*. 2010;183:1744-50.
46. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. *Science*. 2002;296:1883-6.
47. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. *Nature*. 2004;427:695.
48. Ma Y, Hou Y, Liu B, Li X, Yang S, Ma J. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. *Anat Rec (Hoboken)*. 2010;293:1847-54.
49. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. *Curr Opin Genet Dev*. 2011;21:73-9.
50. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. *Nat Rev Cancer*. 2005;5:735-43.
51. Afonso J, Longatto-Filho A, Baltazar F, et al. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. *Eur J Surg Oncol*. 2011;37:811-7.
52. Bambrury RM, Rosenberg JE. Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. *Front Pharmacol*. 2013;4:3.
53. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. *Nature*. 2011;473:298-307.
54. Videira PA, Piteira AR, Cabral MG, et al. Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. *Urol Int*. 2011;86:95-101.
55. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. *J Nucl Med*. 2011;52:497-500.
56. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. *FASEB J*. 2002;16:771-80.
57. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. Rapamycin inhibits in vitro growth and release of angiogenic factors in human bladder cancer. *Urology*. 2009;73:665-8; discussion 668-9.
58. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. *Ann Oncol*. 2012;23:2663-70.
59. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. *Histopathology*. 2011;58:1054-63.
60. Schultz L, Albadine R, Hicks J, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. *Cancer*. 2010;116:5517-26.
61. Afonso J, Longatto-Filho A, VM DAS, Amaro T, Santos LL. Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients. *Oncol Lett*. 2014;8:1447-54.
62. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. *Science*. 2011;331:1559-64.
63. Al-Mulla F, Bitar MS, Taqi Z, Yeung K. RKIP: much more than Raf kinase inhibitory protein. *J Cell Physiol*. 2013;228:1688-702.
64. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. *Cancer Metastasis Rev*. 2012;31:615-20.
65. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Implication of RAF and RKIP genes in urinary bladder cancer. *Pathol Oncol Res*. 2011;17:181-90.
66. Afonso J, Longatto-Filho A, Martinho O, et al. Low RKIP expression associates with poor prognosis in bladder cancer patients. *Virchows Arch*. 2013;462:445-53.
67. Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. *Crit Rev Immunol*. 2009;29:241-54.

68. Chatterjee D, Bai Y, Wang Z. et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. *J Biol Chem.* 2004;279:17515-23.
69. Munoz-Pinedo C, El Mjijad N, Ricci JE. Cancer metabolism: current perspectives and future directions. *Cell Death Dis.* 2012;3:e248.
70. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: insights from the past decade. *Pharmacol Ther.* 2013;137:318-30.
71. Afonso J, Santos LL, Miranda-Goncalves V, et al. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. *Mol Carcinog.* 2014 doi:10.1002/mc.222. [Epub ahead of print].
72. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. *Cancer Genomics Proteomics.* 2010;7:157-69.
73. Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. *Med Oncol.* 2011;28:1363-72.
74. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. *Clin Cancer Res.* 2007;13(15 Pt 1):4407-14.
75. Halestrap AP. The SLC16 gene family - Structure, role and regulation in health and disease. *Mol Aspects Med.* 2013;34:337-49.
76. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. *EMBO J.* 2000;19:3896-904.
77. Choi JW, Kim Y, Lee JH, Kim YS. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. *Urology.* 2014;84:245.e9-15.
78. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. *J Bioenerg Biomembr.* 2012;44:127-39.
79. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. *Proc Natl Acad Sci U S A.* 2005;102:16245-50.
80. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol.* 2006;49:465-6; discussion 475-7.
81. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol.* 2009;182:2195-203.
82. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol.* 2006;176(4 Pt 1):1354-61; discussion 1361-2.
83. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res.* 2006;12:6663-76.
84. Bassi P, Sacco E, De Marco V, Aragona M, Volpe A. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis. *BJU Int.* 2007;99:1007-12.
85. Buchner A, May M, Burger M, et al. Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. *Eur J Surg Oncol.* 2013;39:372-9.
86. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. *Eur Urol.* 2008;54:41-53.
87. Shariat SF, Karakiewicz PI, Godoy G, Lerner SP. Use of nomograms for predictions of outcome in patients with advanced bladder cancer. *Ther Adv Urol.* 2009;1:13-26.
88. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. *BJU Int.* 2010;105:608-13.
89. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol.* 2010;183:68-75.
90. Lotan Y, Bagrodia A, Passoni N, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *Eur Urol.* 2013;64:465-71.